In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the ...

The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

A 3-year research program, funded by the FDA, aims to design the first continuous mRNA-manufacturing platform. Faculty at the Massachusetts Institute of Technology (MIT; MA, USA) will be leading a ...

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.

The "mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA ...